Company / Operating Income
Annovis Bio, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$29.7M
FY2025
5-year range
-$45.0M / -$6.6M
FY2021-FY2025
Trend
+34.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$26M to -$30M over the past 2 years.
Based on SEC 10-K filings.
-$30M in FY2025.
Declined from -$26M to -$30M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 34.1% year-over-year.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$29.7M | +34.1% |
| FY2024 | -$45.0M | -76.5% |
| FY2023 | -$25.5M | +0.0% |
| FY2022 | -$25.5M | -284.2% |
| FY2021 | -$6.6M | -313.6% |
| FY2020 | -$1.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026